Efficacy and effectiveness of raloxifene for preventing or decreasing the danger of subsequent vertebral and/or nonvertebral fractures by improving BMD and minimizing bone turnover in postmenopausal Japanese women with osteoporosis or osteopenia. Other findings suggest that raloxifene is nicely tolerated and may strengthen good quality of life. Having said that, these findings should be regarded as in light of the limitations on the publications plus the threat enefit profile of raloxifene.AcknowledgmentsThe authors thank Shuko Nojiri of Eli Lilly Japan K.K. for her contributions on earlier versions of this overview. Health-related writing assistance was supplied by Julie Monk, PhD and Serina Stretton, PhD, CMPP (Certified Healthcare Publication Expert) of ProScribe Healthcare Communications, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international suggestions for Fantastic Publication Practice (GPP2).DisclosureThe study was funded by Eli Lilly Japan K.K., the manufacturer of raloxifene and teriparatide. SF has received speaker honoraria and consulting costs from Eli Lilly Japan K.K., Asahi-Kasei, Astellas, Chugai, Daiichi-Sankyo, Eisai, Ono,submit your manuscript | dovepressClinical Interventions in Aging 2014:DovepressDovepressSystematic Thymidylate Synthase Inhibitor medchemexpress overview of raloxifene in Japan 18. Mithal A, Ebeling P. The Asia-Pacific Regional Audit. Epidemiology, Costs and Burden of Osteoporosis in 2013. Nyon, Switzerland: International Osteoporosis Foundation; 2013. Obtainable from: iofbonehealth.org/sites/default/files/media/PDFs/Regional 20 Audits/2013-Asia_Pacific_Audit_0_0.pdf. Accessed August 5, 2014. 19. Committee of Japanese Guidelines for the Prevention and Remedy of Osteoporosis. Japanese Suggestions for the Prevention and Treatment of Osteoporosis. Tokyo: Life Science; 2011. 20. Harada A, Matsui Y, Mizuno M, Tokuda H, Niino N, Ohta T. Japanese orthopedists’ interests in prevention of fractures within the elderly from falls. Osteoporos Int. 2004;15(7):560?66. 21. Iwamoto J, Sato Y, Takeda T, Matsumoto H. Efficacy of antiresorptive agents for stopping fractures in Japanese patients with an enhanced fracture danger: critique in the literature. Drugs Aging. 2012;29(3): 191?03. 22. Cranney A, Adachi JD. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf. 2005;28(eight):721?30. 23. Kanis JA, IRAK1 site Johnell O, Black DM, et al. Effect of raloxifene on the threat of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis with the Numerous Outcomes of Raloxifene Evaluation trial. Bone. 2003;33(three):293?00. 24. Takada J, Miki T, Imanishi Y, et al. Effects of raloxifene treatment around the structural geometry of your proximal femur in Japanese females with osteoporosis. J Bone Miner Metab. 2010;28(5):561?67. 25. Uusi-Rasi K, Beck TJ, Semanick LM, et al. Structural effects of raloxifene around the proximal femur: results in the Multiple Outcomes of Raloxifene Evaluation Trial. Osteoporos Int. 2006;17(4): 575?86. 26. Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010;21(4):655?66. 27. Boivin G, Lips P, Ott SM, et al. Contribution of raloxifene and calcium and vitamin D3 supplementation towards the enhance of your degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab. 2003;88(9):4199?205. 28. Nakamura T, Liu JL, Morii H, et al. Effect of raloxifene on c.